Last reviewed 2026-04-20 · How we verify

Xigduo XR

At a glance

Approved indications

No approved indications tracked.

Common side effects

No common side effects on file.

Key clinical trials

• A Clinical Study in Healthy Adults to See How the Body Processes and How Safe a Tablet That Combines Gemigliptin, Dapagliflozin, and Metformin is, Compared With Taking Zemiglo and Xigduo XR Together While Fasting. (PHASE1)
• A Clinical Study to See How the Body Handles and How Safe a Combination Tablet of Gemigliptin, Dapagliflozin, and Metformin 50/10/1000mg is Compared to Taking Gemigliptin 50mg Separately With Dapagliflozin/Metformin 10/1000mg in Healthy Adults After a Meal (PHASE1)
• Efficacy of FDC Regimen of Dapagliflozin/Metformin Compared to Co-administered Dual Therapy on Glycemic Control, Satisfaction and Adherence in Chinese Patients With T2DM (PHASE4)
• Study of Safety and Efficacy of Dapagliflozin + Metformin XR Versus Metformin XR in Participants With HR+, HER2-, Advanced Breast Cancer While on Treatment With Alpelisib and Fulvestrant (PHASE2)
• Adjuvant Therapy With Letrozole in Induction of Ovulation With Polycystic Ovarian Syndrome (PHASE3)
• of Sodium Glucose Cotransporter-2 Inhibitors on Metabolic, Hormonal and Clinical Parameters in PCO (PHASE3)
• Effect of Dapagliflozin/Metformin XR vs Monotherapies on Anthropometric Indicators in Obesity (PHASE4)
• Evaluation of SGLT2-i Effectivness and Safety in Elderly Type 2 Diabetes Patients

Primary sources

Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.

Competitive intelligence

For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:

• Xigduo XR CI brief — competitive landscape report
• Xigduo XR updates RSS · CI watch RSS
• AstraZeneca portfolio CI